January 17, 2007 -- Forest Laboratories announced third quarter income for 2007 of 78 cents per share, up from 57 cps a year ago, and far ahead of the Reuters estimate, which was 66 cps. Forest also upped its full FY2007 estimates based on stronger than projected performance of its branded drugs. Despite is discounted P/E, Forest has solid drug products, an interesting pipeline and expected news flow. We explain why we are cautiously optimistic about the stock...
